Retinitis Pigmentosa (RP) Market, By Route of Administration, By Diagnosis, By Treatment Type, By Disease Type, By End-Users, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

Description

The Retinitis Pigmentosa (RP) Market size was valued at US$ 14,789.90 Million in 2024, expanding at a CAGR of 7.4% from 2025 to 2032.

Retinitis Pigmentosa (RP) is a group of inherited retinal disorders that cause progressive vision loss by damaging the retina, the light-sensitive tissue in the back of the eye. Individuals with RP typically have reduced night vision, gradual peripheral vision loss, and, in the advanced stages, complete blindness. The RP market is primarily driven by improved diagnosis of inherited retinal diseases, increased access to genetic testing, and rapid advances in gene therapy, stem-cell therapy, and optogenetic approaches that allow for more targeted and personalized treatment options. However, market growth is limited by the high cost of gene therapies and the scarcity of approved treatments beyond Luxturna. Key market trends include increased investment in AAV- and CRISPR-based therapeutic platforms, as well as a greater emphasis on early genetic screening.

Retinitis Pigmentosa (RP) Market- Market Dynamics

Rising Healthcare Expenditure Drives Growth In The Retinitis Pigmentosa Market

The increase in healthcare expenditure is expected to drive future growth in the retinitis pigmentosa market. Healthcare expenditure is the total amount of money spent on healthcare goods and services, such as medical treatments, medications, hospitalizations, and preventive care, over a given time period, indicating the overall cost of healthcare provision within a population. Healthcare spending is increasing as the cost of advanced medical technologies rises, populations age, and chronic diseases become more prevalent. Healthcare spending for retinitis pigmentosa is concentrated on improving diagnostic methods, developing effective treatments, and providing supportive care to manage vision loss. For example, according to the National Institutes of Health, a US-based government agency, healthcare spending in the United States increased by 4.1% in 2022 to $4.5 trillion, representing a faster growth rate than the 3.2% increase observed in 2021. As a result, rising healthcare costs are fueling the growth of the retinitis pigmentosa industry.

Retinitis Pigmentosa (RP) Market- Segmentation Analysis:

The worldwide market is segmented on the basis of Route of Administration, Diagnosis, Treatment Type, Disease Type, End-Users, and Region.

In treatment type segment, the gene therapy category is expected to remain a key growth driver throughout the forecast period. Gene therapy for retinitis pigmentosa focuses on delivering functional genes to patient cells to combat disease-causing mutations. Luxturna (voretigene neparvovec-rzyl) is the only FDA-approved therapy for biallelic RPE65 mutations, which restores functional gene expression in retinal cells. Beyond Luxturna, several candidates are making progress in clinical trials, utilizing AAV and other vector technologies to target a broader range of mutations. Continued investment from leading biopharmaceutical companies is boosting development activity and shaping the segment's upward trajectory. For instance, in May 2025, Beacon Therapeutics Holdings Limited reported 6-month interim safety and efficacy results from the Phase 2 DAWN trial of the Company's lead program, laru-zova (laruparetigene zovaparvovec), in patients with X-linked retinitis pigmentosa (XLRP).

Based on Treatment Type segment, Vitamin A supplements remain an essential and historically significant segment of the RP market because vitamin A (specifically, retinol palmitate) has long been studied for its ability to slow photoreceptor degeneration in some RP patients. In the absence of broadly approved gene therapies (for many genetic subtypes), vitamin A has provided a relatively simple, low-tech supplement that may delay the decline in retinal function. Because RP is genetically heterogeneous, nutritional interventions such as vitamin A provide patients with a low-cost, scalable option, especially in settings where advanced therapies are unavailable or as a complementary measure. Vitamin A supplementation exemplifies how more traditional, non-gene-based treatments remain part of the therapeutic mix, even in a market dominated by sophisticated therapies. According to the NEI, a trial supported by the institute (1984-1992) discovered that taking 15,000 IU of vitamin A palmitate daily could slow the rate of functional retinal decline (measured using ERG).

Retinitis Pigmentosa (RP) Market- Geographical Insights

In 2025, North America emerged as a significant region, accounting for more than 45.2% of the market. The region benefits from advanced healthcare infrastructure, significant R&D investments, and a rising incidence of retinal disease. Regulatory support from agencies such as the FDA expedites the approval of innovative therapies, resulting in market growth. The growing awareness of genetic disorders, as well as the demand for effective treatments, are driving this expansion. The United States is the primary contributor, with key players including Regeneron Pharmaceuticals and Spark Therapeutics leading the way. Canada also plays an important role, focusing on R&D initiatives. Collaborations between biotech firms and academic institutions characterize the competitive landscape, thereby expanding the pipeline of novel therapies. The presence of major pharmaceutical companies ensures a strong market environment that promotes innovation and accessibility.

United States Retinitis Pigmentosa (RP) Market- Country Insights

North America, particularly the United States, Canada is known for its large concentration of major players such as pharmaceutical companies, which actively pursue the development of novel therapies for better treatment. For instance, in August 2024, Ocugen, Inc., a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, announced that Health Canada has issued a "No Objection Letter" to begin the OCU400 Phase 3 liMeliGhT clinical trial in Canada. OCU400 is a modifier gene therapy product candidate for retinitis pigmentosa (RP). These are focused on the development of novel therapeutics, which will boost regional market growth.

Retinitis Pigmentosa (RP) Market- Competitive Landscape:

The Retinitis Pigmentosa market is competitive, with a diverse range of stakeholders including pharmaceutical companies, biotechnology firms, academic institutions, research organizations, and healthcare providers. These organizations are involved in a variety of activities, including research and development of new therapies, manufacturing and commercialization of existing treatments, and providing healthcare services to retinitis pigmentosa patients. Government agencies, including the National Institutes of Health (NIH) in the United States and the European Commission's Horizon 2020 program, fund and support retinitis pigmentosa research and development initiatives. These organizations play an important role in encouraging innovation, facilitating collaborations, and advancing therapeutic discoveries in the field of ophthalmology.

Recent Developments:

In December 2024, Bausch + Lomb, a subsidiary of Bausch Health, has acquired Elios Vision Inc., the developer of the ELIOS system, a minimally invasive glaucoma surgery (MIGS) procedure that uses an excimer laser. This acquisition demonstrates Bausch + Lomb's commitment to providing advanced glaucoma treatment solutions, thereby improving patient care around the world.

In May, 2024, The EYE-RD Global Registry was introduced by Johnson & Johnson at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). This non-interventional global registry is the first of its kind and aims to collect longitudinal clinical data on patients with inherited retinal diseases (IRDs), such as X-linked retinitis pigmentosa. The registry's goal is to fill knowledge gaps by providing real-world insights into disease progression and patient experiences, which will aid in IRD research, diagnosis, and treatment strategies.

In August 2025, Novartis (CH) has announced a strategic collaboration with a leading biotechnology company to co-develop a novel gene therapy to treat Retinitis Pigmentosa. This collaboration is expected to leverage both companies' genetic research expertise, potentially shortening the development timeline and expanding the therapeutic options available to patients. Such collaborations not only strengthen Novartis' research capabilities, but also reflect an industry-wide trend toward collaborative innovation.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL RETINITIS PIGMENTOSA (RP) MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Bausch Health Companies Inc.
Novartis AG
Ionis Pharmaceuticals, Inc.
AGTC
MeiraGTx Limited
ReNeuron Group plc
ProQR Therapeutics
Sun Pharmaceutical Industries Ltd.
Allergan
Astellas Pharma Inc.
AstraZeneca
Caladrius Biosciences, Inc.
Genethon
Gensight Biologics
Johnson & Johnson Private Limited
Orphagen Pharmaceuticals, Inc
Clino Corporation
Spark Therapeutics, Inc
Grupo Ferrer International, S.A.
Nanovector S.r.l
Mimetogen Pharmaceuticals Inc.
Others

GLOBAL RETINITIS PIGMENTOSA (RP) MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

Topical
Oral
Others

GLOBAL RETINITIS PIGMENTOSA (RP) MARKET, BY DIAGNOSIS- MARKET ANALYSIS, 2019 - 2032

Electroretinogram
Genetic Testing
Visual Field Testing
Others

GLOBAL RETINITIS PIGMENTOSA (RP) MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2019 - 2032

Retinal Implants
Vitamin A Supplements
Calcium channel blockers
Docosahexaenoic acid (DHA)
Gene Therapy
Others

GLOBAL RETINITIS PIGMENTOSA (RP) MARKET, BY DISEASE TYPE- MARKET ANALYSIS, 2019 - 2032

Autosomal Dominant
X-linked RP
Autosomal Recessive

GLOBAL RETINITIS PIGMENTOSA (RP) MARKET, BY END-USERS- MARKET ANALYSIS, 2019 - 2032

Hospitals
Homecare
Specialty Clinics
Others

GLOBAL RETINITIS PIGMENTOSA (RP) MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA

Product Code: ANV5749

1. Retinitis Pigmentosa (RP) Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Retinitis Pigmentosa (RP) Market Snippet by Route of Administration
- 2.1.2. Retinitis Pigmentosa (RP) Market Snippet by Diagnosis
- 2.1.3. Retinitis Pigmentosa (RP) Market Snippet by Treatment Type
- 2.1.4. Retinitis Pigmentosa (RP) Market Snippet by Disease Type
- 2.1.5. Retinitis Pigmentosa (RP) Market Snippet by End-Users
- 2.1.6. Retinitis Pigmentosa (RP) Market Snippet by Country
- 2.1.7. Retinitis Pigmentosa (RP) Market Snippet by Region
2.2. Competitive Insights

3. Retinitis Pigmentosa (RP) Key Market Trends

3.1. Retinitis Pigmentosa (RP) Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Retinitis Pigmentosa (RP) Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Retinitis Pigmentosa (RP) Market Opportunities
3.4. Retinitis Pigmentosa (RP) Market Future Trends

4. Retinitis Pigmentosa (RP) Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Retinitis Pigmentosa (RP) Market: Impact of Escalating Geopolitical Tensions

5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts

6. Retinitis Pigmentosa (RP) Market Landscape

6.1. Retinitis Pigmentosa (RP) Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Retinitis Pigmentosa (RP) Market - By Route of Administration

7.1. Overview
- 7.1.1. Segment Share Analysis, By Route of Administration, 2024 & 2032 (%)
- 7.1.2. Topical
- 7.1.3. Oral
- 7.1.4. Others

8. Retinitis Pigmentosa (RP) Market - By Diagnosis

8.1. Overview
- 8.1.1. Segment Share Analysis, By Diagnosis, 2024 & 2032 (%)
- 8.1.2. Electroretinogram
- 8.1.3. Genetic Testing
- 8.1.4. Visual Field Testing
- 8.1.5. Others

9. Retinitis Pigmentosa (RP) Market - By Treatment Type

9.1. Overview
- 9.1.1. Segment Share Analysis, By Treatment Type, 2024 & 2032 (%)
- 9.1.2. Retinal Implants
- 9.1.3. Vitamin A Supplements
- 9.1.4. Calcium channel blockers
- 9.1.5. Docosahexaenoic acid (DHA)
- 9.1.6. Gene Therapy
- 9.1.7. Others

10. Retinitis Pigmentosa (RP) Market - By Disease Type

10.1. Overview
- 10.1.1. Segment Share Analysis, By Diagnosis, 2024 & 2032 (%)
- 10.1.2. Autosomal Dominant
- 10.1.3. X-linked RP
- 10.1.4. Autosomal Recessive

11. Retinitis Pigmentosa (RP) Market - By End-Users

11.1. Overview
- 11.1.1. Segment Share Analysis, By End-Users, 2024 & 2032 (%)
- 11.1.2. Hospitals
- 11.1.3. Homecare
- 11.1.4. Specialty Clinics
- 11.1.5. Others

12. Retinitis Pigmentosa (RP) Market- By Geography

12.1. Introduction
- 12.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
12.2. North America
- 12.2.1. Overview
- 12.2.2. Retinitis Pigmentosa (RP) Key Manufacturers in North America
- 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.2.4. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.2.5. North America Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
- 12.2.6. North America Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
- 12.2.7. North America Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
- 12.2.8. North America Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 12.2.9. U.S.
  - 12.2.9.1. Overview
  - 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.2.9.3. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.2.9.4. U.S. Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
  - 12.2.9.5. U.S. Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.2.9.6. U.S. Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
  - 12.2.9.7. U.S. Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 12.2.10. Canada
  - 12.2.10.1. Overview
  - 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.2.10.3. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.2.10.4. Canada Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
  - 12.2.10.5. Canada Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.2.10.6. Canada Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
  - 12.2.10.7. Canada Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
12.3. Europe
- 12.3.1. Overview
- 12.3.2. Retinitis Pigmentosa (RP) Key Manufacturers in Europe
- 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.3.4. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.3.5. Europe Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
- 12.3.6. Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
- 12.3.7. Europe Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
- 12.3.8. Europe Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 12.3.9. Germany
  - 12.3.9.1. Overview
  - 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.9.3. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.9.4. Germany Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
  - 12.3.9.5. Germany Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.3.9.6. Germany Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
  - 12.3.9.7. Germany Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 12.3.10. UK
  - 12.3.10.1. Overview
  - 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.10.3. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.10.4. UK Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
  - 12.3.10.5. UK Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.3.10.6. UK Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
  - 12.3.10.7. UK Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 12.3.11. France
  - 12.3.11.1. Overview
  - 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.11.3. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.11.4. France Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
  - 12.3.11.5. France Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.3.11.6. France Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
  - 12.3.11.7. France Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 12.3.12. Italy
  - 12.3.12.1. Overview
  - 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.12.3. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.12.4. Italy Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
  - 12.3.12.5. Italy Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.3.12.6. Italy Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
  - 12.3.12.7. Italy Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 12.3.13. Spain
  - 12.3.13.1. Overview
  - 12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.13.3. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.13.4. Spain Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
  - 12.3.13.5. Spain Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.3.13.6. Spain Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
  - 12.3.13.7. Spain Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 12.3.14. The Netherlands
  - 12.3.14.1. Overview
  - 12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.14.3. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.14.4. The Netherlands Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
  - 12.3.14.5. The Netherlands Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.3.14.6. The Netherlands Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
  - 12.3.14.7. The Netherlands Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 12.3.15. Sweden
  - 12.3.15.1. Overview
  - 12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.15.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.15.4. Sweden Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
  - 12.3.15.5. Sweden Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.3.15.6. Sweden Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
  - 12.3.15.7. Sweden Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 12.3.16. Russia
  - 12.3.16.1. Overview
  - 12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.16.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.16.4. Russia Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
  - 12.3.16.5. Russia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.3.16.6. Russia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
  - 12.3.16.7. Russia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 12.3.17. Poland
  - 12.3.17.1. Overview
  - 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.17.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.17.4. Poland Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
  - 12.3.17.5. Poland Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.3.17.6. Poland Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
  - 12.3.17.7. Poland Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 12.3.18. Rest of Europe
  - 12.3.18.1. Overview
  - 12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.18.3. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.18.4. Rest of the Europe Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
  - 12.3.18.5. Rest of the Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.3.18.6. Rest of the Europe Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
  - 12.3.18.7. Rest of the Europe Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
12.4. Asia Pacific (APAC)
- 12.4.1. Overview
- 12.4.2. Retinitis Pigmentosa (RP) Key Manufacturers in Asia Pacific
- 12.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.4.4. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.4.5. APAC Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
- 12.4.6. APAC Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
- 12.4.7. APAC Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
- 12.4.8. APAC Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 12.4.9. China
  - 12.4.9.1. Overview
  - 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.9.3. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.9.4. China Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
  - 12.4.9.5. China Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.4.9.6. China Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
  - 12.4.9.7. China Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 12.4.10. India
  - 12.4.10.1. Overview
  - 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.10.3. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.10.4. India Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
  - 12.4.10.5. India Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.4.10.6. India Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
  - 12.4.10.7. India Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 12.4.11. Japan
  - 12.4.11.1. Overview
  - 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.11.3. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.11.4. Japan Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
  - 12.4.11.5. Japan Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.4.11.6. Japan Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
  - 12.4.11.7. Japan Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 12.4.12. South Korea
  - 12.4.12.1. Overview
  - 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.12.3. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.12.4. South Korea Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
  - 12.4.12.5. South Korea Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.4.12.6. South Korea Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
  - 12.4.12.7. South Korea Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 12.4.13. Australia
  - 12.4.13.1. Overview
  - 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.13.3. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.13.4. Australia Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
  - 12.4.13.5. Australia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.4.13.6. Australia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
  - 12.4.13.7. Australia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 12.4.14. Indonesia
  - 12.4.14.1. Overview
  - 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.14.3. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.14.4. Indonesia Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
  - 12.4.14.5. Indonesia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.4.14.6. Indonesia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
  - 12.4.14.7. Indonesia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 12.4.15. Thailand
  - 12.4.15.1. Overview
  - 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.15.3. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.15.4. Thailand Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
  - 12.4.15.5. Thailand Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.4.15.6. Thailand Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
  - 12.4.15.7. Thailand Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 12.4.16. Philippines
  - 12.4.16.1. Overview
  - 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.16.3. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.16.4. Philippines Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
  - 12.4.16.5. Philippines Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.4.16.6. Philippines Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
  - 12.4.16.7. Philippines Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 12.4.17. Rest of APAC
  - 12.4.17.1. Overview
  - 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.17.3. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.17.4. Rest of APAC Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
  - 12.4.17.5. Rest of APAC Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.4.17.6. Rest of APAC Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
  - 12.4.17.7. Rest of APAC Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
12.5. Latin America (LATAM)
- 12.5.1. Overview
- 12.5.2. Retinitis Pigmentosa (RP) Key Manufacturers in Latin America
- 12.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.5.4. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.5.5. LATAM Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
- 12.5.6. LATAM Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
- 12.5.7. LATAM Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
- 12.5.8. LATAM Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 12.5.9. Brazil
  - 12.5.9.1. Overview
  - 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.9.3. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.5.9.4. Brazil Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
  - 12.5.9.5. Brazil Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.5.9.6. Brazil Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
  - 12.5.9.7. Brazil Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 12.5.10. Mexico
  - 12.5.10.1. Overview
  - 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.10.3. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.5.10.4. Mexico Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
  - 12.5.10.5. Mexico Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.5.10.6. Mexico Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
  - 12.5.10.7. Mexico Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 12.5.11. Argentina
  - 12.5.11.1. Overview
  - 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.11.3. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.5.11.4. Argentina Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
  - 12.5.11.5. Argentina Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.5.11.6. Argentina Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
  - 12.5.11.7. Argentina Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 12.5.12. Colombia
  - 12.5.12.1. Overview
  - 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.12.3. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.5.12.4. Colombia Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
  - 12.5.12.5. Colombia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.5.12.6. Colombia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
  - 12.5.12.7. Colombia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 12.5.13. Rest of LATAM
  - 12.5.13.1. Overview
  - 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.13.3. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.5.13.4. Rest of LATAM Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
  - 12.5.13.5. Rest of LATAM Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.5.13.6. Rest of LATAM Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
  - 12.5.13.7. Rest of LATAM Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
12.6. Middle East and Africa
- 12.6.1. Overview
- 12.6.2. Retinitis Pigmentosa (RP) Key Manufacturers in Middle East and Africa
- 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.6.4. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.6.5. Middle East and Africa Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
- 12.6.6. Middle East and Africa Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
- 12.6.7. Middle East and Africa Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
- 12.6.8. Middle East and Africa Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 12.6.9. Saudi Arabia
  - 12.6.9.1. Overview
  - 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.9.3. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.9.4. Saudi Arabia Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
  - 12.6.9.5. Saudi Arabia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.6.9.6. Saudi Arabia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
  - 12.6.9.7. Saudi Arabia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 12.6.10. United Arab Emirates
  - 12.6.10.1. Overview
  - 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.10.3. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.10.4. United Arab Emirates Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
  - 12.6.10.5. United Arab Emirates Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.6.10.6. United Arab Emirates Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
  - 12.6.10.7. United Arab Emirates Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 12.6.11. Israel
  - 12.6.11.1. Overview
  - 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.11.3. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.11.4. Israel Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
  - 12.6.11.5. Israel Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.6.11.6. Israel Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
  - 12.6.11.7. Israel Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 12.6.12. Turkey
  - 12.6.12.1. Overview
  - 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.12.3. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.12.4. Turkey Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
  - 12.6.12.5. Turkey Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.6.12.6. Turkey Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
  - 12.6.12.7. Turkey Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 12.6.13. Algeria
  - 12.6.13.1. Overview
  - 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.13.3. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.13.4. Algeria Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
  - 12.6.13.5. Algeria Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.6.13.6. Algeria Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
  - 12.6.13.7. Algeria Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 12.6.14. Egypt
  - 12.6.14.1. Overview
  - 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.14.3. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.14.4. Egypt Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
  - 12.6.14.5. Egypt Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.6.14.6. Egypt Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
  - 12.6.14.7. Egypt Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 12.6.15. Rest of MEA
  - 12.6.15.1. Overview
  - 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.15.3. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.15.4. Rest of MEA Market Size and Forecast, By Diagnosis, 2019 - 2032 (US$ Million)
  - 12.6.15.5. Rest of MEA Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 12.6.15.6. Rest of MEA Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
  - 12.6.15.7. Rest of MEA Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Retinitis Pigmentosa (RP) Industry

13.1. Competitive Benchmarking
- 13.1.1. Competitive Dashboard
- 13.1.2. Competitive Positioning
13.2. Company Profiles
- 13.2.1. Bausch Health Companies Inc.
- 13.2.2. Novartis AG
- 13.2.3. Ionis Pharmaceuticals, Inc.
- 13.2.4. AGTC
- 13.2.5. MeiraGTx Limited
- 13.2.6. ReNeuron Group plc
- 13.2.7. ProQR Therapeutics
- 13.2.8. Sun Pharmaceutical Industries Ltd.
- 13.2.9. Allergan
- 13.2.10. Astellas Pharma Inc.
- 13.2.11. AstraZeneca
- 13.2.12. Caladrius Biosciences, Inc.
- 13.2.13. Genethon
- 13.2.14. Gensight Biologics
- 13.2.15. Johnson & Johnson Private Limited
- 13.2.16. Orphagen Pharmaceuticals, Inc
- 13.2.17. Clino Corporation
- 13.2.18. Spark Therapeutics, Inc
- 13.2.19. Grupo Ferrer International, S.A.
- 13.2.20. Nanovector S.r.l
- 13.2.21. Mimetogen Pharmaceuticals Inc.
- 13.2.22. Others

14. 360 Degree Analyst View

15. Appendix

15.1. Research Methodology
15.2. References
15.3. Abbreviations
15.4. Disclaimer
15.5. Contact Us